Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 4.3M | 57.1% |
| Gross Profit | 3.7M | 72.4% |
| Cost of Revenue | 650,000 | 4.8% |
| Operating expense | 12M | 14.5% |
| Net Income | -7.6M | 30.9% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 182M | 13.2% |
| Total Liabilities | 52M | 91.7% |
| Total Equity | 130M | 2.7% |
| Shares Outstanding | 71M | 0.1% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | 22M | 278.5% |
| Cash from investing | 2.8M | 514.7% |
| Cash from financing | 22,000 | 300% |
EPS
Financial Highlights for Aclaris Therapeutics in Q3 '24
Aclaris Therapeutics reported a revenue of 4.3M, which is a 57.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 3.7M, marking a 72.4% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 650,000, a 4.8% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 12M, showing a -14.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -7.6M, showing a 30.9% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Aclaris Therapeutics with growth in revenue, gross profit, and net income.
